China's biotechnology sector is rapidly expanding, leveraging a strategy that focuses on speeding up drug manufacturing and reducing costs. Wuxi, near Shanghai, has become a major hub where companies such as Wuxi AppTec are streamlining drug discovery and production, serving both Chinese and international pharmaceutical firms like Pfizer and AstraZeneca. Despite geopolitical tensions and tariffs, Chinese biotech stocks have surged over 60% this year, reflecting market confidence in this more manufacturing-oriented approach compared to the US emphasis on cutting-edge breakthroughs.